EUCTR2017-000214-27-RO进行中（未招募）1 期
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of the efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Patients with Moderate-to-Severe Plaque Psoriasis - CF101-301PS
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 407
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, 18 to 80 years of age, inclusive;
- •2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement =10%, as judged by the Investigator;
- •3. PASI score =12 (Appendix 3);
- •4. Static PGA =3 (Appendix 2);
- •5. Candidate for systemic treatment or phototherapy for psoriasis;
- •6. Duration of psoriasis of at least 6 months;
- •7. Females of childbearing potential must have a negative serum pregnancy test at screening;
- •8. Female subjects of childbearing potential must use highly effective contraception throughout the course of the trial and for 3 months after. Highly effective methods include hormonal contraception (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants; each method must be used with a barrier method, preferably male condom), intrauterine device or system, tubal ligation, partner vasectomy, or dual (male plus female) barrier methods (each barrier method must be used with a hormonal method).
- •Female subjects who use a hormonally based method must agree to use it in conjunction with a barrier method. Female partners of male study subjects should consider using one of the above methods of contraception as well. Post-menopausal status is defined as menopause for at least 1 year prior to the Screening Visit and must be confirmed by an elevated serum FSH level.
- •9. Male subjects must refrain from sperm donation during treatment and until at least 90 days after the end of study drug dosing. Male subjects with fertile or pregnant partners must agree to use condoms throughout the course of the trial and for 3 months after.
- •10. Ability to complete the study in compliance with the protocol; and
- •11. Ability to understand and provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 107
排除标准
- •1. Psoriasis limited to erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis in the absence of plaque psoriasis;
- •2. Prior treatment with apremilast within 4 weeks prior to the Baseline visit, or
- •contraindication to apremilast;
- •3. Treatment with systemic retinoids, corticosteroids, tofacitinib, or immunosuppressive agents (e.g., methotrexate, cyclosporine) within 4 weeks of the Baseline visit;
- •4. Treatment with a biological agent (etanercept, adalimumab, efalizumab, infliximab, ustekinumab, alefacept, secukinumab, or others, including investigational agents) within a period of time equal to 5 times its circulating half-life, or 30 days, whichever is longer, prior to the Baseline visit;
- •5. Treatment with high potency topical dermatological corticosteroids (Class I-III in US, Class III-IV in Europe), Vitamin D analogs, keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit;
- •6. Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period;
- •7. Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit, or anticipated need for such drugs during the study period, unless dose has been stable for 3 months prior to the Screening visit and will remain stable throughout the trial;
- •8. Serum creatinine level greater than 1.25 times the laboratory’s upper limit of normal atScreening;
- •9. Liver aminotransferase levels greater than 1.5 times the laboratory’s upper limit of normal at Screening;
- •10. QTcF interval on Screening Visit ECG or on average of triplicate Baseline Visit ECGs >450 milliseconds (msec) for males or > 470 msec for females (except when QT prolongation is associated with right or left bundle branch block, in which case enrollment is allowed);
- •11. A condition which increases proarrhythmic risk, including hypokalemia, hypomagnesemia, or congenital Long QT Syndrome;
- •12. Heart disease which is, in the Investigator’s judgment, clinically unstable;
- •13. Ongoing or planned use of a concomitant medication that is on the CredibleMedsTM list of drugs known to cause Torsades des Pointes (Appendix 7);
- •14. Active gastrointestinal disease which could interfere with the absorption of oral medication;
- •15. Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the Investigator;
- •16. Active drug or alcohol dependence;
- •17. History of depression or suicidal ideation within the past year;
- •18. Concomitant use of strong cytochrome P450 inducers, e.g., rifampin, phenobarbital, phenytoin, carbamazepine;
- •19. Previous participation in a piclidenoson (CF101) clinical trial;
- •20. Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject’s ability to complete the study, and/or compromise the objectives of the study;
- •21. Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to the Screening visit.
研究者
相似试验
进行中（未招募）
不适用
Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist TherapyEUCTR2010-022758-18-HUJanssen-Cilag International N.V.675
进行中（未招募）
1 期
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVRespiratory Syncytial VirusMedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002023-11-DEJanssen-Cilag International NV737
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients with Moderately to Severely Active Crohn’s DiseaseModerately to severely active Crohn's diseaseMedDRA version: 17.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-022759-42-HUJanssen-Cilag International N.V.612
进行中（未招募）
1 期
Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate CancerEUCTR2017-003295-31-HUPfizer Inc., 235 East 42nd Street, New York, NY 100171,037
进行中（未招募）
1 期
A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- andHigh-risk Pulmonary arterial hypertension (PAH) Patients.EUCTR2021-000199-12-ITACCELERON PHARMA INC.662